John Wilkinson is set to step down from his role as MHRA medical device chief in October, after vaginal mesh campaigners claimed the agency didn't take the scandal 'seriously'.
Last month, health watchdog NICE caused outrage when it ruled that vaginal mesh could be used by the NHS under certain circumstances. But pelvic mesh campaigners celebrated a major win later on in the month, when medical giant Johnson & Johnson was forced to pay almost $10 million to avoid going to trial over its role in the scandal.
And now it’s been announced that John Wilkinson, the director of devices at the UK Medicines and Healthcare products Regulatory Agency, will step down in October.
Wilkinson has spent seven years in the role, helping to shape European device regulations as well as procedures at MHRA.
But vaginal mesh campaigners say the agency didn’t do enough to support patients and survivors.
Vaginal mesh has been linked with a number of serious complications, which are often permanent. Reported side effects include chronic urinary tract infections, pain during sex and irreversible nerve damage. Some women even say that they have been left housebound as a result of the procedure.
‘The agency is not an effective watchdog,’ Scottish Mesh Survivors campaigner Elaine Holmes told the Scottish Parliament in 2014. ‘It does not take our concerns seriously. We have written to it a number of times and telephoned it, but we get standard copy and paste replies. The agency does not listen to us.’
Prince Harry praises “legend” Gareth Thomas as he opens up about HIV diagnosis
Is your blood pressure secretly killing you? Survey reveals shocking number of people don’t realise they suffer from the condition
Medical herbalist reveals the three key herbs she uses to support women with the menopause
Politicians have also pitched in to criticise MHRA’s handling of the pelvic mesh scandal. ‘When the public petitions committee took evidence from it, we learned that its “detailed analysis” amounted to three postgraduate students doing a desktop exercise for two weeks at a cost of £20,000,’ Jackson Carlaw revealed during a parliamentary debate in 2016.
In another debate, he suggested that the figure might actually be as high as £40,000.
Others agreed that this evidence showed that the agency’s device review process was ‘not fit for purpose’ and ‘completely inadequate’.